Free Trial
NASDAQ:DRTS

Alpha Tau Medical Q1 2024 Earnings Report

Alpha Tau Medical logo
$3.27 +0.14 (+4.47%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$3.22 -0.04 (-1.38%)
As of 07:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alpha Tau Medical EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.13
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Alpha Tau Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alpha Tau Medical Announcement Details

Quarter
Q1 2024
Time
TAS
Conference Call Date
Monday, May 20, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Alpha Tau Medical's Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Alpha Tau Medical Earnings Headlines

Alpha Tau Medical Ltd. (DRTS) - Yahoo Finance
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More Alpha Tau Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alpha Tau Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alpha Tau Medical and other key companies, straight to your email.

About Alpha Tau Medical

Alpha Tau Medical (NASDAQ:DRTS), a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

View Alpha Tau Medical Profile

More Earnings Resources from MarketBeat